SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is trending as the community debates its long-term viability, with vocal supporters citing newfound institutional interest and potential ETF exposure, while skeptics point to stagnant price action and broken roadmap promises. Retail traders remain divided between those accumulating in anticipation of a cycle rotation and critics dismissing the token as a failed project.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is seeing a significant surge in community engagement and price momentum, largely fueled by its growing narrative as a leading privacy-focused asset and recent momentum across the broader crypto ecosystem. Traders are actively debating its potential for long-term growth and comparing its trajectory to Bitcoin, while closely monitoring key resistance levels and institutional developments.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors digest its long-term strategy to mitigate the upcoming patent expiration of its blockbuster oncology drug Keytruda by expanding its pipeline through AI-driven research and strategic acquisitions. Meanwhile, the community remains actively focused on speculative buyout rumors involving smaller biotech firms and the potential for combination therapies to become the new standard of care in oncology.

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Cg Oncology Inc.

CG Oncology is attracting significant attention as investors position for upcoming BLA filings and clinical trial readouts, with the community actively debating its competitive standing against other bladder cancer therapies. Discussion centers on the strength of trial data and the potential for the stock to benefit from its institutional backing and future regulatory milestones.

Billions is the global human and AI network, built on mobile-first verification to scale the internet of value. We uniquely verify the identity and uniqueness of humans and AI agents, empowering users with personalized experiences and rewards.  ‍Our network is designed to be accessible, scalable, and anonymous, making trust between humans and AI seamless and intuitive for everyone.

TillBilly

TillBilly is driving intense debate as investors weigh its potential as a momentum play against concerns over low circulating supply and possible market manipulation. The community remains sharply divided, with bulls pointing to the token's explosive volatility and chart patterns while bears express skepticism regarding project legitimacy and long-term price stability.

Bank of Montreal engages in the provision of banking and financial services to individuals and institutions. It operates through the following segments: Canadian Personal and Commercial Banking (Canadian P&C), United States Personal and Commercial Banking (U.S. P&C), BMO Wealth Management, BMO Capital Markets, and Corporate Services. The company was founded by Robert Armour, John C. Bush, Austin Cuvillier, George Garden, Horatio Gates, James Leslie, George Moffatt, John Richardson and Thomas A. Turner on June 23, 1817 and is headquartered in Montreal, Canada.

Bank of Montreal - MicroSectors Oil & Gas Exploration & Production -3X Inverse Leveraged

MicroSectors™ Oil & Gas Exploration & Production -3X Inverse Leveraged ETNs

The community is actively discussing volatile price action in OILD, with many traders debating entry and exit points for this leveraged inverse ETF amidst uncertainty in global oil supply and production trends. Discussions frequently focus on the discrepancy between the ticker's price movements and underlying oil futures, leading to intense speculation about shorting energy producers.

Pattern Group, Inc. engages brands in global ecommerce marketplaces by leveraging proprietary technology and AI. It acquires inventory from brand partners to sell to consumers through online marketplaces, utilizing vast data sets, sophisticated machine learning, and AI models. The company optimizes and automates all levers of ecommerce growth for global brands, enabling full control over advertising, content management, logistics and fulfillment, pricing, forecasting, and customer service. Pattern Group was founded by David Wright and Melanie Alder in 2013 and is headquartered in Lehi, UT.

Pattern Group Inc. - Ordinary Shares - Series A

Pattern Group

Pattern Group is generating significant investor buzz following an earnings report that highlighted robust revenue growth and an optimistic outlook, with the community actively comparing the stock's profitability and valuation to other high-profile tech names. Investors are closely monitoring the company's strategic pivot toward AI-enabled e-commerce infrastructure, viewing it as a catalyst for potential market re-rating and sustained long-term performance.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is attracting intense community interest as a core piece of financial infrastructure, fueled by massive on-chain trading volumes and its emergence as a dominant decentralized derivatives exchange. Investors are actively debating its long-term potential as a 'generational' asset, closely monitoring on-chain accumulation patterns, liquidation data, and institutional exposure that differentiate it from typical speculative tokens.

Phillips 66 engages in the processing, transportation, storage, and marketing of fuels and other related products. The company operates through the following segments: Midstream, Chemicals, Refining, Renewable Fuels, Marketing and Specialties, and Corporate and Other. The Midstream segment provides crude oil and refined products transportation, terminal, and processing services, as well as natural gas, natural gas liquids, and liquefied petroleum gas transportation, storage, processing, and marketing services. The Chemicals segment produces and markets petrochemicals and plastics worldwide. The Refining segment refines crude oil and other feedstocks into petroleum products such as gasoline, distillates, and aviation fuels. The Marketing and Specialties segment purchases for resale and markets refined petroleum products such as base oils and lubricants, and power generation operations. The Renewable Fuels segment processes renewable feedstocks into renewable products at the Rodeo Renewable Energy Complex (Rodeo Complex) and at Humber Refinery. The company was founded in 1875 and is headquartered in Houston, TX.

Phillips 66

Phillips 66 is currently trending as a focus for both institutional and retail investors, driven by significant interest from activist investor Elliott Investment Management and a strategic shift to streamline its business model. The community is actively debating the company's long-term value, with discussions centering on the potential for asset spin-offs, operational improvements, and how the firm is balancing refining operations with midstream investments amidst broader energy sector volatility.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Fresenius Medical Care (FMS) is a focal point of community discussion as investors monitor its involvement in the adoption of DefenCath for bloodstream infection prevention across its dialysis facilities. Market participants are actively comparing the company's progress and potential for patient-outcome improvements against other operators, while closely tracking broader legislative lobbying efforts and its strategic interest in new renal care acquisitions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway...

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Participate in Upcoming Investor Conferences REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., May 18, 2026 ROCKVILLE, Md., May 18, 2026 /PRNewswire...

Regenxbio (RGNX) Q1 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

RGNX Stock On Track For Worst Day Ever As Big Q1 Loss, Cash Concerns Eclipse Duchenne Trial Success  

Equity

REGENXBIO on Thursday reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy.


REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval

REGENXBIO reports positive Phase 3 Duchenne trial data as RGX-202 met its primary endpoint with strong safety results.read more...

Regenxbio Shares Rise After Positive Duchenne Trial Results

Regenxbio Shares Rise After Positive Duchenne Trial Results...

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -26.94% and -73.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights PR Newswire ROCKVILLE, Md., May 14...

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of RGX-202

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of RGX-202 REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of...

REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary 

The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.


REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.25	--	--	N/A
Q1 '26	-$1.34	-$1.72	-28.65%	MISSED
Q4 '25	-$0.88	-$1.30	-48.52%	MISSED
Q3 '25	-$1.30	-$1.20	7.81%	BEAT
Q2 '25	-$0.94	-$1.38	-47.14%	MISSED

RGNX
Regenxbio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Compact View

Latest RGNX News

RGNXRegenxbio Inc